Abstract
The aim of this work was assessment of the efficacy and tolerability of two different regimens for retreatment of hepatitis C virus (HCV) patients who failed to respond to SOF/DCV-based therapy. This prospective study included 104 HCV patients who failed to respond to SOF/DCV-based therapy. Patients were randomly allocated to two groups. Efficacy and tolerability were assessed. The 12-week sustained virological response (SVR12) rates were 96% and 94.4% in groups B and A, respectively, with no significant difference (p = 1.000). Most adverse events reported were mild to moderate, with no deaths during the study. Multi-target direct-acting antiviral (DAA) combinations are efficient for retreatment of HCV patients after failure of SOF/DCV-based therapy in real-world management.ClinicalTrials.gov identifier: NCT02992457.
Publication types
-
Clinical Trial
-
Observational Study
-
Retracted Publication
MeSH terms
-
Adult
-
Anilides / administration & dosage
-
Antiviral Agents / administration & dosage*
-
Carbamates / administration & dosage
-
Cyclopropanes
-
Drug Therapy, Combination
-
Female
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Imidazoles / administration & dosage
-
Lactams, Macrocyclic
-
Macrocyclic Compounds / administration & dosage
-
Male
-
Middle Aged
-
Proline / analogs & derivatives
-
Prospective Studies
-
Pyrrolidines
-
Ribavirin / administration & dosage
-
Ritonavir / administration & dosage
-
Simeprevir / administration & dosage
-
Sofosbuvir / administration & dosage
-
Sulfonamides
-
Treatment Outcome
-
Valine / analogs & derivatives
Substances
-
Anilides
-
Antiviral Agents
-
Carbamates
-
Cyclopropanes
-
Imidazoles
-
Lactams, Macrocyclic
-
Macrocyclic Compounds
-
Pyrrolidines
-
Sulfonamides
-
ombitasvir
-
Ribavirin
-
Proline
-
Simeprevir
-
Valine
-
daclatasvir
-
Ritonavir
-
paritaprevir
-
Sofosbuvir
Associated data
-
ClinicalTrials.gov/NCT02992457